Skip to main content
main-content

Dulaglutide

News

01-13-2021 | Dulaglutide | News

Dulaglutide reduces total CVD burden in REWIND population

Participants in the REWIND trial achieved a significant reduction in total cardiovascular disease burden with dulaglutide versus placebo, report the investigators.

01-11-2021 | Dulaglutide | News

AWARD 11 supports higher dulaglutide doses

Dulaglutide doses of 3.0 and 4.5 mg are significantly more efficacious than the standard doses, with similar safety profiles, report the AWARD 11 investigators.

12-21-2020 | Dulaglutide | News

Longer treatment persistence with dulaglutide vs other GLP-1 receptor agonists in type 2 diabetes

Dulaglutide is associated with better treatment persistence and lower rates of treatment modification versus other glucagon-like peptide‑1 receptor agonists in people with type 2 diabetes, suggests a study of Swedish health registries.

Read more

Related topics

Superior

Related

Opinion

10-23-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Glucagon-like peptide-1 receptor agonist use in acute myocardial infarction

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of glucagon-like peptide-1 receptor agonists in patients affected by acute myocardial infarction.

In depth

07-02-2019 | Dulaglutide | Podcast | Article

REWIND, DECLARE, and high-risk diabetes patients

How will the findings of the REWIND trial and the DECLARE-TIMI 58 renal outcomes analysis affect treatment decisions for high-risk diabetes patients without overt cardiovascular disease? medwireNews asks Kamlesh Khunti.

10-17-2017 | GLP-1 agonists | Feature | Article

GLP-1 receptor agonists: Cardiovascular trials and triumphs

With four GLP-1 receptor agonists now having published cardiovascular outcome data, medwireNews takes a look at how the experts are interpreting the conflicting findings, and what they mean for prescribing decisions.

Journal articles and book chapters

08-31-2018 | GLP-1 agonists | Review | Article

Cardiovascular effects of different GLP-1 receptor agonists in patients with type 2 diabetes

Bahtiyar G, Pujals-Kury J, Sacerdote A. Curr Diab Rep 2018; 18: 92. doi: 10.1007/s11892-018-1043-z

06-21-2018 | Hypoglycemia | Review | Article

Hypoglycemia among patients with type 2 diabetes: Epidemiology, risk factors, and prevention strategies

Silbert R et al. Curr Diab Rep 2018; 18: 53. doi: 10.1007/s11892-018-1018-0

06-05-2018 | Cardiovascular outcomes | Review | Article

Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: A comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials

Zhuang X et al. Cardiovasc Diabetol 2018; 17: 79. doi: 10.1186/s12933-018-0722-z

Image Credits